Table 5.
Characteristics of Patients Included in the MDV Data Analysis
| n, mean | %, SD | |
|---|---|---|
| N | 3553 | - |
| Sex, n, % | ||
| Male | 2623 | 73.82% |
| Female | 930 | 26.18% |
| Age, mean, SD | 65.87 | 14.57 |
| Comorbidities, n, % | ||
| Respiratory disease | 1352 | 38.05% |
| Cardiovascular disease | 2214 | 62.31% |
| Infectious diseases | 1104 | 31.07% |
| Immune deficiencies | 25 | 0.70% |
| Diabetes | 1128 | 31.75% |
| Diseases of the genitourinary system | 1748 | 49.20% |
| Concomitant drugs, n, % | ||
| Glycerin enema | 944 | 26.57% |
| Colonel tablets | 15 | 0.42% |
| Teleminsoft suppositories | 258 | 7.26% |
| Bio-three | 64 | 1.80% |
| Pursennid tablets | 1196 | 33.66% |
| Laxoberon solution | 515 | 14.49% |
| Loperamide hydrochloride | 57 | 1.60% |
| Magnesium oxide | 1054 | 29.67% |
| New lecicarbon supp. | 361 | 10.16% |
| Major middle-strengthening decoction | 204 | 5.74% |
| Cravit fine granule | 3 | 0.08% |
| Cravit tablets | 404 | 11.37% |
| Kefral | 38 | 1.07% |
| Bactramin combination tablet | 95 | 2.67% |
| Firstcin intravenous | 25 | 0.70% |
| Flomox | 273 | 7.68% |
| Bladderon tablets | 4 | 0.11% |
| Minomycin tablets | 74 | 2.08% |
| Cravit intravenous drip infusion | 38 | 1.07% |
| Zosyn | 187 | 5.26% |
| Pentcillin | 76 | 2.14% |
| Fosmicin-s for injection | 26 | 0.73% |
| Unasyn-s for intravenous use | 278 | 7.82% |
MDV: Medical Data Vision Inc.; SD: standard difference